AstraZeneca (AZN) P/E ratio

P/E ratio today
25.8×

AstraZeneca (AZN) trades at 25.8× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 28.1×. That is 3.5% lower than the 29.1× of fiscal 2024. Figures as of 18 Nov 2026, 09:53 UTC, from Yahoo Finance.

Key facts

P/E ratio today
25.8×
P/E ratio, fiscal 2025
28.1×
Change on fiscal 2024
−3.5%
Highest on record
64.3×fiscal 2022
Lowest on record
28.1×fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

AstraZeneca P/E ratio, in more detail

Today's figure is 8.3% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 64.3× in fiscal 2022 and the lowest 28.1× in fiscal 2025. Today's P/E ratio is at or below every one of the 4 fiscal year-ends on record; their median is 32.2×.

History · 4 fiscal years

P/E ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

AstraZeneca P/E ratio, year by year

AstraZeneca (AZN) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
Today25.8×—$182.27—
202528.1× 3.5% down$183.86$6.54
202429.1× 17.6% down$131.04$4.50
202335.4× 45.0% down$134.70$3.81
202264.3×—$135.60$2.11

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

P/E ratio at health care companies of similar size

P/E ratio of AstraZeneca and comparable companies
CompanyP/E ratio
Merck & Co MRK144.8×
UnitedHealth Group UNH22.2×
Novartis NVS30.4×
AstraZeneca AZN25.8×
Thermo Fisher Scientific TMO36.2×
Amgen AMGN26.5×

Price over the last twelve months' earnings per share, as the market data feed reports it.

More on AZN

AstraZeneca, figure by figure

AstraZeneca (AZN) overview: price, valuation and scorecardAll health care companies by market value

AstraZeneca P/E ratio: questions and answers

What is AstraZeneca's P/E ratio?

AstraZeneca (AZN) trades at 25.8× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 28.1×. That is 3.5% lower than the 29.1× of fiscal 2024.

Is AstraZeneca's P/E ratio high or low compared with its own history?

Today's P/E ratio is at or below every one of the 4 fiscal year-ends on record; their median is 32.2×.

What are the highest and lowest P/E ratio figures on record for AstraZeneca?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 64.3× in fiscal 2022 and the lowest 28.1× in fiscal 2025.

How is AstraZeneca's P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For AstraZeneca it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AstraZeneca (AZN) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/AZN/pe-ratio

Underlying data: Yahoo Finance.